Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Ovarian Cancer Clinical Trials in Chicago | 301 Studies

Clinical Trials Ovarian CancerChicago

Ovarian Cancer Clinical Trials in Chicago

Find 301 clinical trials for ovarian cancer near Chicago, Illinois. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Chicago

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 41-60 of 301 trials

CompletedCombination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003322·Birmingham, Alabama and 66 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedDocetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00004037·Birmingham, Alabama and 66 others

CompletedBevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the OvaryThis phase II trial studies how well bevacizumab works in treating patients with sex cord-stromal tumors of the ovary that have come back.NCT00748657·Los Angeles, California and 35 others

TerminatedStudy of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian CancerThis is a Phase 1a/1b study of SC-003 as a single agent and in combination with ABBV-181 in patients with platinum-resistant/refractory ovarian cancer.NCT02539719·Fayetteville, Arkansas and 15 others

TerminatedLiposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.NCT00003380·Birmingham, Alabama and 62 others

RecruitingA Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With GemcitabineThis is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2…NCT03854110·Chicago, Illinois and 3 others

RecruitingSYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryInternational registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool…NCT03452774·Birmingham, Alabama and 67 others

Active not recruitingPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube…NCT02839707·Anchorage, Alaska and 918 others

Active not recruitingStudy to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsThis phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come…NCT06169124·Los Angeles, California and 65 others

CompletedTirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.NCT00020696·Birmingham, Alabama and 53 others

CompletedStudy of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women…NCT03740165·Birmingham, Alabama and 226 others

CompletedAvelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in…NCT01772004·Goodyear, Arizona and 73 others

TerminatedA Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsThis is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics…NCT03717415·San Francisco, California and 8 others

CompletedPaclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell TumorsRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.NCT00003518·Denver, Colorado and 18 others

CompletedQuality of Life in Survivors of Gynecologic CancerRATIONALE: Quality-of-life assessment in cancer survivors may help determine the long-term effects of having had gynecologic cancer and may help improve the quality of life for…NCT00003795·Birmingham, Alabama and 43 others

Active not recruitingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK…NCT02568267·Phoenix, Arizona and 119 others

TerminatedAmifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003624·Orange, California and 7 others

CompletedA Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsThis is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic…NCT03000257·La Jolla, California and 25 others

RecruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialThis ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.NCT05564377·Birmingham, Alabama and 481 others

RecruitingAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerThe intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade…NCT07218809·Birmingham, Alabama and 298 others

PreviousPage 3 of 16Next

Other Conditions in Chicago

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia